Product news

Share this article:
The FDA has approved Sucampo Pharmaceuticals' supplemental NDA for Amitiza (lubiprostone) to treat irritable bowel syndrome with constipation in women 18 years of age or older. As a result of the approval, Sucampo Pharmaceuticals will receive a development milestone payment of $50 million from Takeda in accordance a prior licensing agreement. Sucampo Pharmaceuticals and Takeda will jointly market Amitiza in the US and Canada. 
 
The FDA approved Watson Pharmaceuticals' Mixject, a new delivery system for Trelstar (triptorelin pamoate for injectable suspension), a palliative treatment for advanced prostate cancer.
Share this article:

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.